vimarsana.com
Home
Live Updates
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights : vimarsana.com
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
– Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected in September 2023 – – Plasma pyrophosphate to...
Related Keywords
Boston ,
Massachusetts ,
United States ,
Yves Sabbagh ,
Inozyme Pharma ,
Matt Pera ,
Kurt Gunter ,
Stefan Riley ,
Douglasa Treco ,
European Medicines Agency ,
European Congress ,
Exchange Commission ,
Corporate Communications ,
European Calcified Tissue Society Congress ,
Linkedin ,
Development Rd Expenses ,
Globenewswire Inc ,
Paediatric Committee ,
Drug Administration ,
Facebook ,
Twitter ,
Global Development Strategy ,
Inozyme Or Company ,
Nasdaq ,
Inozyme Pharma Inc ,
Development Strategy Update ,
Medicines Agency ,
Calcified Tissue Society Congress ,
Private Securities Litigation Reform Act ,
Annual Report ,
Consolidated Balance Sheet Data ,
Consolidated Statements ,
Markets ,
vimarsana.com © 2020. All Rights Reserved.